Emergent BioSolutions Inc.
EBS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $0 | $1 | $2 |
| - Cash | $0 | $0 | $1 | $1 |
| + Debt | $1 | $1 | $1 | $1 |
| Enterprise Value | $1 | $1 | $1 | $3 |
| Revenue | $1 | $1 | $1 | $2 |
| % Growth | -0.5% | -6.1% | -37% | – |
| Gross Profit | $0 | $0 | $0 | $1 |
| % Margin | 36% | 34.3% | 42.3% | 44.7% |
| EBITDA | $0 | -$0 | $0 | $1 |
| % Margin | 5.1% | -4.5% | 1.4% | 28.4% |
| Net Income | -$0 | -$1 | -$0 | $0 |
| % Margin | -18.3% | -72.5% | -18.9% | 12.4% |
| EPS Diluted | -3.6 | -14.85 | -4.47 | 4.06 |
| % Growth | 75.8% | -232.2% | -210.1% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | $0 |